Impact of Gender on Transcatheter Aortic Valve Implantation Outcomes.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
15 10 2020
Historique:
received: 16 06 2020
revised: 16 07 2020
accepted: 17 07 2020
pubmed: 28 8 2020
medline: 13 11 2020
entrez: 27 8 2020
Statut: ppublish

Résumé

Previous studies indicate that women who underwentwho underwent transcatheter aortic valve implantation (TAVI) have poorer 30-day outcomes compared with men. However, the effect of gender as a prognostic factor for long-term outcomes following TAVI remains unclear. Between 2008 and 2018, all patients (n = 683) who underwent TAVI in 2 centres in Melbourne, Australia were prospectively included in a registry. The primary end-point was long-term mortality. The secondary end points were Valve Academic Research Consortium-2 (VARC-2) in-hospital complications and mortality at 30-days and 1-year. Of 683 patients, 328 (48%) were women. Women had a higher mean STS-PROM score (5.2 ± 3.1 vs 4.6 ± 3.5, p < 0.001) but less co-morbidities than men. Women had a significantly higher in-hospital bleeding rates (3.3% vs 1.0%, Odds Ratio 4.21, 95% confidence interval [CI] 1.16 to15.25, p = 0.027) and higher 30-day mortality (2.4% vs 0.3%, hazard ratio [HR] 8.75, 95% CI 1.09 to 69.6, p = 0.040) than men. Other VARC-2 outcomes were similar between genders. Overall mortality rate was 36% (246) over a median follow up of 2.7 (interquartile rang [IQR] 1.7 to 4.2) years. Median time to death was 5.3 (95% CI 4.7 to 5.7) years. One-year mortality was similar between genders (8.3% vs 7.8%), as was long-term mortality (HR = 0.91, 95% CI 0.71 to 1.17, p = 0.38). On multivariable analysis, female gender was an independent predictor for 1-year mortality (HR = 2.33, 95% CI 1.11 to 4.92, p = 0.026), but not long-term mortality (HR = 0.78, 95% CI 0.54 to 1.14, p = 0.20). In the women only cohort, STS-PROM was the only independent predictor of long-term mortality (HR 1.88, 95% CI 1.42 to 2.48, p < 0.001). In conclusion, women had higher rates of peri-procedural major bleeding and 30-day mortality following TAVI. However, long-term outcomes were similar between genders.

Identifiants

pubmed: 32843145
pii: S0002-9149(20)30787-6
doi: 10.1016/j.amjcard.2020.07.052
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

98-104

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Julia Stehli (J)

Department of Cardiology, Alfred Hospital, Melbourne, Australia; Cardiovascular Institute, Epworth Healthcare, Melbourne, Australia; Monash University, Melbourne, Australia.

Misha Dagan (M)

Department of Cardiology, Alfred Hospital, Melbourne, Australia.

Sarah Zaman (S)

Monash University, Melbourne, Australia; Monash Cardiovascular Research Centre, Monash Heart, Melbourne, Australia.

Ji Quan Samuel Koh (JQS)

Department of Cardiology, Alfred Hospital, Melbourne, Australia.

Edward Quine (E)

Department of Cardiology, Alfred Hospital, Melbourne, Australia.

Natalia Gouskova (N)

Marcus Institute for Ageing Research, Hebrew SeniorLife, Boston, MA, USA.

Claudia Crawford (C)

Department of Cardiology, Alfred Hospital, Melbourne, Australia.

Michael Dong (M)

Department of Cardiology, Alfred Hospital, Melbourne, Australia.

Shane Nanayakkara (S)

Department of Cardiology, Alfred Hospital, Melbourne, Australia; Baker Heart and Diabetes Institute, Melbourne, Australia; Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.

Nay M Htun (NM)

Department of Cardiology, Alfred Hospital, Melbourne, Australia.

Dion Stub (D)

Department of Cardiology, Alfred Hospital, Melbourne, Australia; Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.

Ronald Dick (R)

Cardiovascular Institute, Epworth Healthcare, Melbourne, Australia.

Antony Walton (A)

Department of Cardiology, Alfred Hospital, Melbourne, Australia; Cardiovascular Institute, Epworth Healthcare, Melbourne, Australia.

Stephen J Duffy (SJ)

Department of Cardiology, Alfred Hospital, Melbourne, Australia; Baker Heart and Diabetes Institute, Melbourne, Australia; Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia. Electronic address: s.duffy@alfred.org.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH